Rezolute To Participate In Upcoming Investor Conferences

2026-05-11 07:01:26

(MENAFN- GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the“Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: H.C. Wainwright 4^th Annual BioConnect Investor Conference
Date: May 19, 2026

Event: Jefferies Global Healthcare Conference
Date: June 2-4, 2026

Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit

Rezolute Contacts:

Christen Baglaneas
...
508-272-6717

Carrie McKim
...
336-608-9706

MENAFN11052026004107003653ID1111096099

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.